International patterns and trends of childhood and adolescent cancer, 1978-2012

Zhao, Yawen; Sun, Pengyan; Xiao, Jingyuan; Jin, Lan; Ma, Ning; Li, Zhe; Feng, Guoshuang; Huang, Huang; Deziel, Nicole C.; Ma, Xiaomei; Ni, Xin; Zhang, Yawei

doi:10.1016/j.jncc.2022.02.001

Cited by 6 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal cell carcinoma (RCC) is the most common and most lethal malignancy of the urinary system with an increasing annual incidence rate of approximately 1.1% worldwide 1,2 . In China, the Ivyspring International Publisher number of kidney cancer cases increases by about 76,000 annually, and an average of 27,000 people die from RCC every year 3 .…”

Section: Introductionmentioning

confidence: 99%

Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma

Xu¹,

Wu²,

Liu³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma

Xu¹,

Wu²,

Liu³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

“…As one of the most common cancers in the world, lung cancer is characterized by late diagnosis, poor prognosis, and high mortality (Dundr et al, 2021;Zhao et al, 2022;Zheng et al, 2022). NSCLC is more common compared to small-cell lung cancer (SCLC), accounting for 85% of lung cancer patients (Fintelmann et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic and immunologic implications of the epithelial–mesenchymal transition model reveal a novel role of SFTA2 in prognosis of non-small-cell lung carcinoma

Zhai

Chen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the second most common cancer worldwide, and most deaths are associated with epithelial–mesenchymal transition (EMT). Therefore, this study aimed to explore the role of EMT-related transcriptomic profiles in NSCLC and the effect of EMT-based signatures on clinical diagnosis, prognosis, and treatment responses for patients with NSCLC. After integrating the transcriptomics and clinicopathological data, we first constructed EMT clusters (C1 and C2) using machine learning algorithms, found the significant relationship between EMT clusters and survival outcomes, and then explored the impact of EMT clusters on the tumor heterogeneity, drug efficiency, and immune microenvironment of NSCLC. Prominently, differential-enriched tumor-infiltrated lymphocytes were found between EMT clusters, especially the macrophages and monocyte. Next, we identified the most significantly down-regulated gene SFTA2 in the EMT clusters C2 with poor prognosis. Using RT-qPCR and RNA-seq data from the public database, we found prominently elevated SFTA2 expression in NSCLC tissues compared with normal lung tissues, and the tumor suppressor role of SFTA2 in 82 Chinese patients with NSCLC. After Cox regression and survival analysis, we demonstrated that higher SFTA2 expression in tumor samples significantly predicts favorable prognosis of NSCLC based on multiple independent cohorts. In addition, the prognostic value of SFTA2 expression differs for patients with lung adenocarcinoma and squamous cell carcinoma. In conclusion, this study demonstrated that the EMT process is involved in the malignant progression and the constructed EMT clusters exerted significant predictive drug resistance and prognostic value for NSCLC patients. In addition, we first identified the high tumoral expression of SFTA2 correlated with better prognosis and could serve as a predictive biomarker for outcomes and treatment response of NSCLC patients.

show abstract

“…Cancer remains the leading disease burden worldwide (1)(2)(3). Radiation therapy (RT) plays an important role in the treatment of cancers and is an effective local treatment method.…”

Section: Introductionmentioning

confidence: 99%

Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects

Wang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Radiation therapy (RT) not only can directly kill tumor cells by causing DNA double-strand break, but also exerts anti-tumor effects through modulating local and systemic immune responses. The immunomodulatory effects of RT are generally considered as a double-edged sword. On the one hand, RT effectively enhances the immunogenicity of tumor cells, triggers type I interferon response, induces immunogenic cell death to activate immune cell function, increases the release of proinflammatory factors, and reshapes the tumor immune microenvironment, thereby positively promoting anti-tumor immune responses. On the other hand, RT stimulates tumor cells to express immunosuppressive cytokines, upregulates the function of inhibitory immune cells, leads to lymphocytopenia and depletion of immune effector cells, and thus negatively suppresses immune responses. Nonetheless, it is notable that RT has promising abscopal effects and may achieve potent synergistic effects, especially when combined with immunotherapy in the daily clinical practice. This systematic review will provide a comprehensive profile of the latest research progress with respect to the immunomodulatory effects of RT, as well as the abscopal effect of radioimmunotherapy combinations, from the perspective of biological basis and clinical practice.

show abstract

International patterns and trends of childhood and adolescent cancer, 1978-2012

Cited by 6 publications

References 67 publications

Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma

Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma

Transcriptomic and immunologic implications of the epithelial–mesenchymal transition model reveal a novel role of SFTA2 in prognosis of non-small-cell lung carcinoma

Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects

Contact Info

Product

Resources

About